Culture-Negative Nodules in a Neutropenic Child: Probable Is Not Proven
A 10-year-old boy with relapsed acute myeloid leukemia is in the third week of neutropenia (absolute neutrophil count 80/µL) after chemotherapy. He has persistent fever despite meropenem and vancomycin, and chest CT shows two peripheral nodules with a halo sign. Blood cultures are sterile. Serum galactomannan index is 1.9 and, two days later, 2.3; he received IVIG 5 days ago and is on piperacillin-tazobactam. Bronchoalveolar lavage galactomannan is 0.7, and fungal culture is negative at 5 days. The oncology team asks whether the negative culture means the nodules are not fungal and whether antifungal therapy can be stopped.
1. How do you interpret the galactomannan results and the negative fungal culture in this host?
Read the worked answer
In a profoundly neutropenic child with persistent fever and CT nodules with a halo sign, repeated serum galactomannan indices of 1.9 and 2.3 are strongly suggestive of invasive aspergillosis; the BAL index of 0.7 is also above the usual 0.5–1.0 cutoff depending on assay. Culture is insensitive-positive in only a minority of proven cases-and a negative culture at 5 days does not exclude Aspergillus, especially after antifungal exposure or when the lesion is angioinvasive and paucibacillary.
IVIG and piperacillin-tazobactam can cause false-positive galactomannan, but the combination of high, rising indices, a high-risk host, and typical imaging makes a false positive unlikely. The appropriate interpretation is probable invasive pulmonary aspergillosis, not 'culture-negative, nonfungal nodules.'
2. What treatment and further diagnostic steps do you recommend, and what monitoring is required?
Read the worked answer
Start or continue mold-active therapy: voriconazole is first-line, with isavuconazole or liposomal amphotericin B as alternatives. Do not stop antifungals on the basis of negative culture. Obtain ophthalmologic evaluation for endophthalmitis and consider brain MRI if neurologic signs appear. For a peripheral nodule with a halo sign, image the chest again in 1–2 weeks; if the lesion is near a large vessel or the patient is worsening, consider surgical resection for diagnosis and source control.
If voriconazole is used, check trough levels after 5–7 days and monitor liver enzymes, visual symptoms, and interactions with chemotherapy and other azoles. Obtain a tissue diagnosis when feasible, but do not delay therapy for it. Review prior azole prophylaxis because breakthrough aspergillosis may be resistant.
3. The oncology team is worried about overtreatment and wants a 7-day antifungal trial then stop if afebrile. How do you respond?
Read the worked answer
A short 'trial then stop' is not appropriate for probable invasive aspergillosis. Response in neutropenic patients is slow; fever may resolve with neutrophil recovery while the infection persists, and stopping early risks progression, especially with angioinvasive disease. Duration is individualized: continue until lesions stabilize or resolve and immunosuppression improves, often weeks to months, with imaging and galactomannan trends guiding decisions.
Stewardship means using the right mold-active drug, avoiding unnecessary antibacterial escalation, and stopping therapy when there is convincing evidence of an alternative diagnosis-not stopping simply because cultures are negative. If the team remains uncertain, seek tissue or repeat BAL and infectious diseases consensus rather than a fixed 7-day course.